GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Debt-to-EBITDA

RASP (Actavia Life Sciences) Debt-to-EBITDA : -1.07 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Actavia Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.30 Mil. Actavia Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Actavia Life Sciences's annualized EBITDA for the quarter that ended in Mar. 2024 was $-0.28 Mil. Actavia Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -1.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Actavia Life Sciences's Debt-to-EBITDA or its related term are showing as below:

RASP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.9   Med: -0.1   Max: 0.87
Current: -0.88

During the past 11 years, the highest Debt-to-EBITDA Ratio of Actavia Life Sciences was 0.87. The lowest was -1.90. And the median was -0.10.

RASP's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.5 vs RASP: -0.88

Actavia Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for Actavia Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Debt-to-EBITDA Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.10 -1.90 0.87 -0.05

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.54 -1.08 -0.46 -1.07

Competitive Comparison of Actavia Life Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Actavia Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Debt-to-EBITDA falls into.



Actavia Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Actavia Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.211 + 0) / -4.23
=-0.05

Actavia Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.304 + 0) / -0.284
=-1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Actavia Life Sciences  (OTCPK:RASP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Actavia Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences Headlines

No Headlines